Clayface collected an estimated $10.4 million in its domestic opening-day tally, putting DC Studios’ horror film ahead of an expanding Elizabeth Holmes documentary in Saturday’s box-office reports. The result gives Warner Bros. an early lead for the October 23–25 weekend, although forecasts remain provisional and include business that has not yet occurred.
The central figures are consistent across Variety and The Numbers: Clayface leads Friday, while A24’s You Can See Everything earned approximately $6.1 million as it reached more theaters. The contest pairs a comic-book property reshaped as horror with a nonfiction film whose audience is growing beyond its initial release.
Neither result establishes profitability or a lasting change in moviegoing. What the early receipts do show is that two very different theatrical strategies can attract paying audiences during the same weekend, without either requiring the opening numbers associated with a major summer blockbuster.
A DC character enters through horror
Warner Bros. released Clayface in North America on October 23. The official synopsis identifies James Watkins as director and Tom Rhys Harries as Matt Hagen, an actor who turns to an experimental treatment after being disfigured. Mike Flanagan and Hossein Amini wrote the screenplay, using a character from DC’s catalog.
The commercial proposition rests on that combination: a recognizable entertainment brand supporting a story sold through a specific genre. In interviews with the Associated Press, DC leaders described a deliberately character-focused horror project rather than a conventional superhero adventure. AP and TheWrap reported a production budget of about $40 million, considerably limiting the investment being tested compared with a much larger production.
That cost figure is reported, rather than a complete public accounting. It excludes the question of how much was spent to market and distribute the film. An opening gross therefore measures audience spending, not money returned to the producer or profit earned by the studio.
A documentary expands its reach
A24’s competitor follows Elizabeth Holmes in the period before her imprisonment and beyond. The distributor’s film page credits Nathan Fielder and Lance Oppenheim as directors and lists an October 16 theatrical release. Its running time is two hours and 55 minutes, making its strong early receipts especially notable for a lengthy nonfiction release.
The documentary expanded from 855 locations to 2,655 for its second weekend, according to The Numbers and TheWrap. That increase changes the meaning of its rising total: many more theaters can now sell tickets. Growth in overall receipts is encouraging for the distributor, but it cannot alone establish that demand increased at each existing location.
The two films consequently offer different tests. Clayface is measuring how widely an established comics brand can travel through horror. You Can See Everything is measuring how far a documentary can expand after its first audience has arrived. Comparing the totals is useful for ranking the weekend; understanding the release patterns is necessary to interpret them.
Friday receipts are not weekend results
The opening-day figure for Clayface includes $3.5 million from Thursday previews, The Numbers reported. Those advance screenings are part of the reported opening tally, rather than additional revenue that should be added to it. They also mean the apparent Friday performance includes an audience that chose to attend before the regular opening day.
Saturday forecasts placed Clayface near $24 million for the full domestic weekend. TheWrap put the documentary near $20 million; The Numbers’ model suggested approximately $21 million. These are estimates based on early business and expected attendance patterns, not conflicting final statements of how much audiences have already spent.
The difference matters because a relatively small gap can narrow or widen as Saturday and Sunday sales arrive. Models translate partial receipts into an expected total using assumptions about later attendance. The Numbers explains its comparisons and multipliers, making that uncertainty visible rather than presenting a forecast as a completed result.
A ranking also cannot identify why someone bought a ticket. A viewer may be responding to the subject, a director, advertising, a recommendation or the availability of a convenient screening. The grosses do not separate those motivations. For that reason, the documentary’s expansion should be read as a successful opportunity to reach more viewers so far, rather than proof that nonfiction will broadly displace franchise entertainment. The horror film’s lead likewise does not establish that every lesser-known comics character can sustain a theatrical release.
The next test is staying power
For Warner Bros., the next useful evidence will be how Clayface performs after its first wave of viewers. For A24, it will be whether the larger footprint sustains demand once the expansion weekend passes. Both questions require more observations than the first Saturday report provides.
The immediate finding is narrower but meaningful: a horror adaptation has established an opening-day lead while a documentary is drawing substantial business across a wider release. Final weekend reporting will clarify the ranking. Subsequent attendance, distribution costs and revenue sharing will determine how much commercial value either film ultimately delivers.
